Stevens First Principles Investment Advisors boosted its position in Bristol-Myers Squibb Co (NYSE:BMY) by 475.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,472 shares of the biopharmaceutical company’s stock after purchasing an additional 3,695 shares during the period. Stevens First Principles Investment Advisors’ holdings in Bristol-Myers Squibb were worth $285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also recently made changes to their positions in BMY. First Trust Advisors LP raised its stake in Bristol-Myers Squibb by 10.7% in the second quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock worth $24,130,000 after buying an additional 41,892 shares in the last quarter. Advisor Partners LLC raised its stake in Bristol-Myers Squibb by 6.9% in the third quarter. Advisor Partners LLC now owns 36,961 shares of the biopharmaceutical company’s stock worth $2,356,000 after buying an additional 2,382 shares in the last quarter. Oppenheimer & Co. Inc. raised its stake in Bristol-Myers Squibb by 2.5% in the second quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock worth $19,976,000 after buying an additional 8,813 shares in the last quarter. Israel Discount Bank of New York raised its stake in Bristol-Myers Squibb by 31.8% in the second quarter. Israel Discount Bank of New York now owns 10,515 shares of the biopharmaceutical company’s stock worth $586,000 after buying an additional 2,540 shares in the last quarter. Finally, Dividend Assets Capital LLC bought a new position in Bristol-Myers Squibb in the second quarter worth approximately $737,000. 69.74% of the stock is owned by institutional investors and hedge funds.
BMY has been the topic of several analyst reports. Vetr lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price target on the stock. in a report on Thursday, September 28th. Jefferies Group reaffirmed a “buy” rating and issued a $72.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, September 27th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Citigroup lifted their price target on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a report on Wednesday, October 18th. Finally, Credit Suisse Group reaffirmed a “hold” rating and issued a $61.00 price target (up from $58.00) on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $65.11.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Theodore R. Samuels II acquired 4,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was purchased at an average price of $62.30 per share, with a total value of $249,200.00. Following the transaction, the director now owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb Co (BMY) traded down $0.47 on Thursday, hitting $61.38. 1,351,766 shares of the stock were exchanged, compared to its average volume of 7,136,355. The stock has a market capitalization of $100,670.00, a price-to-earnings ratio of 24.17, a PEG ratio of 2.20 and a beta of 1.18. Bristol-Myers Squibb Co has a 12-month low of $46.01 and a 12-month high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.77 earnings per share. equities research analysts forecast that Bristol-Myers Squibb Co will post 2.99 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a yield of 2.61%. Bristol-Myers Squibb’s payout ratio is currently 62.99%.
TRADEMARK VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/18/bristol-myers-squibb-co-bmy-holdings-increased-by-stevens-first-principles-investment-advisors.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.